These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 33202150)
1. The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS. Li H; Hu Y; Tang H; Li S; Ding H; Zhai S; Zhao R Am J Chin Med; 2020; 48(7):1539-1552. PubMed ID: 33202150 [TBL] [Abstract][Full Text] [Related]
2. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Li H; Chen C; Hu F; Wang J; Zhao Q; Gale RP; Liang Y Leukemia; 2020 Jun; 34(6):1503-1511. PubMed ID: 32372026 [TBL] [Abstract][Full Text] [Related]
5. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907 [TBL] [Abstract][Full Text] [Related]
6. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS. Mishra J; Prasun C; Sahoo PK; Nair MS Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095 [TBL] [Abstract][Full Text] [Related]
7. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV. Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167 [TBL] [Abstract][Full Text] [Related]
8. Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic. Negi M; Chawla PA; Faruk A; Chawla V Bioorg Chem; 2020 Nov; 104():104315. PubMed ID: 33007742 [TBL] [Abstract][Full Text] [Related]
9. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096 [TBL] [Abstract][Full Text] [Related]
10. What are our pharmacotherapeutic options for MERS-CoV? Al-Tawfiq JA; Memish ZA Expert Rev Clin Pharmacol; 2014 May; 7(3):235-8. PubMed ID: 24580083 [TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. Vargas M; Servillo G; Einav S Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567 [TBL] [Abstract][Full Text] [Related]
12. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. Ford N; Vitoria M; Rangaraj A; Norris SL; Calmy A; Doherty M J Int AIDS Soc; 2020 Apr; 23(4):e25489. PubMed ID: 32293807 [TBL] [Abstract][Full Text] [Related]
13. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future]. Ye ZW; Jin DY Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological therapies for patients with human coronavirus infections: a rapid systematic review. Andrade KRC; Carvalho VKDS; Farinasso CM; Lima AA; Silva RB; Wachira VK; Capucho HC; Souza PM; Vanni T; Sachetti CG; Rêgo DF Cien Saude Colet; 2020 Sep; 25(9):3517-3554. PubMed ID: 32876256 [TBL] [Abstract][Full Text] [Related]
15. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics. Aviani JK; Halim D; Soeroto AY; Achmad TH; Djuwantono T Rev Med Virol; 2021 Nov; 31(6):e2225. PubMed ID: 33621405 [TBL] [Abstract][Full Text] [Related]
16. Assessment of the efficacy and safety of Ribavirin in treatment of coronavirus-related pneumonia (SARS, MERS and COVID-19): A protocol for systematic review and meta-analysis. Wang Y; Li W; Jiang Z; Xi X; Zhu Y Medicine (Baltimore); 2020 Sep; 99(38):e22379. PubMed ID: 32957417 [TBL] [Abstract][Full Text] [Related]
17. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418 [TBL] [Abstract][Full Text] [Related]
18. Broad-spectrum coronavirus antiviral drug discovery. Totura AL; Bavari S Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247 [TBL] [Abstract][Full Text] [Related]
19. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. de Wilde AH; Falzarano D; Zevenhoven-Dobbe JC; Beugeling C; Fett C; Martellaro C; Posthuma CC; Feldmann H; Perlman S; Snijder EJ Virus Res; 2017 Jan; 228():7-13. PubMed ID: 27840112 [TBL] [Abstract][Full Text] [Related]
20. Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans. Strayer DR; Dickey R; Carter WA Infect Disord Drug Targets; 2014; 14(1):37-43. PubMed ID: 25019238 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]